Loneliness During the NPIs for the COVID-19 Pandemic in Norway: Risk Factors and Associations With Psychopathology
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04365881|
Recruitment Status : Completed
First Posted : April 28, 2020
Last Update Posted : April 28, 2020
The present study of loneliness during the COVID-19-related NPIs is part of a larger project aiming to investigate psychological reactions and symptoms associated with the current and ongoing governmental initiatives in place in Norway.
The results will lead to a better understanding of the psychological effects on quarantine on the population and consequently will be relevant for the development of tailored prevention and intervention programs fit for pandemic crises.
Objectives Investigate the levels of loneliness in a general population during the strict social distancing government-initiated non-pharmacological interventions (NPIs) for the COVID-19 pandemic.
Investigate risk and resilience factors for loneliness and the associations between loneliness and psychopathology symptoms during the NPIs.
Aims Inform the general public, policy makers, scientists, and health practitioners about the associations of the NPIs with the mental health problem of loneliness and its potential effect on psychopathology.
Provide a foundation for policymakers and health-care professionals to employ interventions that protect the general public against increased psychological suffering and dysfunction during society's handling of pandemics.
|Condition or disease||Intervention/treatment|
|Loneliness, Worry, Rumination, Health Anxiety, Depression, Anxiety||Other: Cross-sectional observational study|
|Study Type :||Observational|
|Actual Enrollment :||10084 participants|
|Official Title:||Loneliness During the Non-pharmacological Epidemiological Interventions for the COVID-19 Pandemic in Norway: Risk Factors and Associations With Psychopathology|
|Actual Study Start Date :||March 31, 2020|
|Actual Primary Completion Date :||April 7, 2020|
|Actual Study Completion Date :||April 7, 2020|
- Other: Cross-sectional observational study
SurveyOther Name: Survey
- UCLA Loneliness Scale-8 (ULS-8) [ Time Frame: From March31st 2020 to April 7th 2020 ]The UCLA Loneliness Scale-8 (ULS-8) measures the frequency and intensity of aspects of the lonely experience, using a 1 (never) to 4 (always) Likert-type scale. A composite score was computed by summing the items after reverse coding when appropriate, such that higher scores indicate greater loneliness. In terms of symptoms, validated measures routinely used in clinical practice to screen symptom-levels suggestive of psychiatric diagnosis were utilized.
- Patient Health Questionnaire-9 (PHQ-9) [ Time Frame: From March31st 2020 to April 7th 2020 ]The Patient Health Questionnaire-9 (PHQ-9)16 consists of nine items covering the DSM-IV criteria for major depression scored on a four-point Likert-scale (0-3), with scores ranging from 0 to 27. High scores on the PHQ-9 reveal greater depression severity and scores above 10 are considered as the cut-off indicative of a depressive diagnosis with a sensitivity and specificity of 88%.16 The PHQ-9 has revealed good psychometric properties, as demonstrated by Kroenke et al. (2001).
- Generalized Anxiety Disorder-7 (GAD-7) [ Time Frame: From March31st 2020 to April 7th 2020 ]The Generalized Anxiety Disorder-7 (GAD-7)17 consists of seven items covering the DSM-IV criteria for GAD on a four-point Likert scale (0-3) with scores ranging from 0 to 21. Higher scores reveal greater GAD symptoms, and scores above 10 are considered as the cut-off indicative of a GAD-diagnosis with a specificity of 82% and sensitivity of 89%.17 The GAD-7 has revealed construct validity and reliability (Kroenke, Spitzer, Williams, Monahan & Löwe, 2007; Löwe et al., 2008).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04365881
|University of Oslo|
|Principal Investigator:||Omid V. E. Ebrahimi, Cand Psychol||University of Oslo and Modum Bad|
|Principal Investigator:||Asle Hoffart, PhD||Modum Bad and University of Oslo|
|Principal Investigator:||Sverre Urnes Johnson, PhD||University of Oslo and Modum Bad|